|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA mRNA was detected by the LightCycler in 28 patients (39%) with pT2 tumors, in 22 patients (38%) with >pT2 tumors, but in only 3 patients (16%) with BPH.
|
12949428 |
2003 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA levels were significantly higher in patients with OCPCa or APCa compared to patients with BPH.
|
15283888 |
2004 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
|
17961073 |
2007 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prostate-specific antigen (PSA) levels are affected by non-cancerous conditions such as benign prostatic hyperplasia, inflammations, and inherited factors.
|
25434496 |
2015 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) lacks specificity and sensitivity in discriminating prostate cancer (PCa) from benign prostatic hyperplasia (BPH) when the total PSA (tPSA) level is between 4 and 10 ng/mL.
|
26954072 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months.
|
28327526 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) is used as an indicative marker of a pathologic condition of the prostate, and the ratio of free PSA (fPSA) to total PSA (tPSA) helps to distinguish benign prostatic hyperplasia (BPH) from prostate cancer (PCa).
|
28383168 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.
|
28430620 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, <i>p</i> < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm<sup>3</sup>, <i>p</i> = 0.02).
|
30186533 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PSA mRNA was not found in patients with BPH, other types of cancer, or in healthy controls.
|
7533062 |
1995 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel splice variant of PSA was identified, PSA-SV5, that may be exploited in clinical diagnosis to distinguish prostate cancer from benign prostate hyperplasia.
|
18222179 |
2008 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A previously developed liquid chromatography-mass spectrometry/mass spectrometry-based strategy was used for multiplex analysis of core-fucosylated prostate-specific antigen (fuc-PSA) and total prostate-specific antigen levels in sera from 50 benign prostate hyperplasia and 100 prostate cancer patients of different aggressiveness (Gleason scores, 5-10) covering the critical gray area (2-10 ng/mL).
|
30907281 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, PSA, apolipoprotein B, fasting blood glucose, cholesterol, HDL, and low-density lipoprotein (LDL) levels were predictors of BPH/LUTS at the initial health examination.
|
31626149 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
All of the patients with benign prostatic hyperplasia and healthy young men had negative RT-PCR results for PSA and PSM.
|
21156999 |
2010 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
All patients with BPH were divided into two groups according to international prostate symptom score (IPSS), prostate specific antigen (PSA) level, Q(max), and prostate volume.
|
21532858 |
2011 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Altogether, several known genes, such as prostate-specific antigen (PSA), human glandular kallikrein 2 (hK2), phosphatidic acid phosphatase type 2a (PAP2a), alpha-tropomyosin, and insulin-like growth factor binding protein 7 (IGFBP-7), as well as an anonymous transcript (EST), were found to be expressed less in PC-3 than in BPH.
|
11169518 |
2001 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.
|
21128595 |
2011 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As a result of analysis using sera from 15 PCa or 15 benign prostate hyperplasia (BPH) patients whose PSA levels were in the "gray zone" (4.0-10.0 ng/mL), 52 glycan structures on PSA were quantitatively observed.
|
30669833 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As BPH-related factors, International Prostate Symptom Score, quality of life, maximal flow rate, postvoid residual volume, prostate-specific antigen, prostate volume, prostate calculi, and medication state for BPH were investigated.
|
31734054 |
2020 |
|
Benign Prostatic Hyperplasia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56-1.28; p=0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76-1.19; p=0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86-1.46; p=0.39). pCA and BPH cases were also compared with PSA-screened controls.
|
17125911 |
2007 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Between 2007 and 2016, fifty patients with biopsy-proven PCa were pair-matched for age and PSA levels, with the same number of benign prostatic hyperplasia (BPH) patients used to validate the diagnostic performance of serum S2,3PSA ratio.
|
28241428 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both miRNA ratios were highly sensitive and more specific than PSA in discriminating localised PCa from BPH.
|
27228285 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BPH induced by TP evoked weight gaining and histological changes of prostate and BBR treatment improved all the detrimental effects not only weight reduction and histological changes but also suppression of prostate-specific antigen (PSA), which is elevated during BPH.
|
30061836 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Comparison of mutation frequency and PSA level in prostate needle biopsies with data of patients with benign prostate hyperplasia (BPH) treated by transurethral resection (TURP), patients with prostatic intraepithelial neoplasia (PIN), and patients with PCa, was made.
|
18225585 |
2008 |
|
Benign Prostatic Hyperplasia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Correlation analyses suggested up-regulation of prostatic ARF6 expression with increasing degree of BPH, as ARF6 expression increased with the content of prostate-specific antigen (PSA) of prostate tissues.
|
31243101 |
2019 |